Sarecycline

Sarecycline
Clinical data
Trade names	Seysara
ATC code	J01AA14 (WHO) ;
Identifiers
	IUPAC name (4S,4aS,5aR,12aR)-4-(Dimethylamino)-1,10,11,12a-tetrahydroxy-7-[[methoxy(methyl)amino]methyl]-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;
CAS Number	1035654-66-0;
PubChem CID	71296095;
ChemSpider	28540486;
UNII	94O110CX2E;
KEGG	D10666;
CompTox Dashboard (EPA)	DTXSID001027924 ;
ECHA InfoCard	100.241.852
Chemical and physical data
Formula	C24H29N3O8
Molar mass	487.509 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC;

Sarecycline (trade name Seysara; development code WC-3035) is a narrow-spectrum tetracycline-derived antibiotic.^[1] In the United States, it was approved by the FDA in October 2018 for the treatment of moderate to severe acne vulgaris.^[2]

Paratek Pharmaceuticals, Inc. licensed the US rights to sarecycline for the treatment of acne in the United States to Actavis, a subsidiary of Allergan, while retaining rights in the rest of the world.^[3]

Allergan initiated a Phase 3 study in December 2014 evaluating the efficacy and safety of sarecycline tablets 1.5 mg/kg per day taken orally for 12 weeks versus placebo in the treatment of acne vulgaris.^[4] Two phase 3 randomized, multi-center, double-blind, placebo-controlled studies evaluating the efficacy and safety of sarecycline in moderate to severe acne reported positive results on 27 March 2017.^[5]

References

^ Zhanel G, Critchley I, Lin LY, Alvandi N (January 2019). "Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris". Antimicrobial Agents and Chemotherapy. 63 (1). doi:10.1128/AAC.01297-18. PMC 6325184. PMID 30397052.
^ "FDA Approves Sarecycline for Moderate to Severe Acne". MedScape. October 2, 2018.
^ "Paratek Pharmaceuticals Inc". Bloomberg.
^ Clinical trial number NCT02320149 for "Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne" at ClinicalTrials.gov
^ "Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne". www.globenewswire.com. 27 March 2017. Retrieved 16 May 2017.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[1] Zhanel G, Critchley I, Lin LY, Alvandi N (January 2019). "Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris". Antimicrobial Agents and Chemotherapy. 63 (1). doi:10.1128/AAC.01297-18. PMC 6325184. PMID 30397052.

[2] "FDA Approves Sarecycline for Moderate to Severe Acne". MedScape. October 2, 2018.

[3] "Paratek Pharmaceuticals Inc". Bloomberg.

[4] Clinical trial number NCT02320149 for "Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne" at ClinicalTrials.gov

[5] "Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne". www.globenewswire.com. 27 March 2017. Retrieved 16 May 2017.

[1]

[2]

[3]

[4]

[5]